New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:08 EDTTSROTESARO and AnaptysBio collaborate on immuno-oncology antibody program
TESARO and AnaptysBio announced a strategic immuno-oncology collaboration under which AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody candidates from these programs are expected to enter clinical trials over the next 18 to 24 months. TESARO will pay an upfront license fee of $17M and provide funding of costs incurred by AnaptysBio related to the development programs. For each development program, AnaptysBio is eligible to receive milestone payments associated with certain U.S. and ex-U.S. regulatory submissions and approvals in multiple indications. AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 12, 2015
08:24 EDTTSROTESARO expands niraparib clinical program, provides update on FY15 milestones
TESARO provided an update on its late-stage programs. New trial of niraparib for the treatment of ovarian cancer to begin in Q1. HRD assay to be incorporated into Phase 3 NOVA trial of niraparib in ovarian cancer. Initial Phase 3 data from NOVA is expected to become available in 2015. FDA PDUFA action date for oral rolapitant is September 4, 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use